

Justification for the selection of a candidate CoRAP substance

Substance Name (Public Name): 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
Chemical Group:
EC Number: 200-076-7
CAS Number: 51-03-6
Submitted by: Swedish Chemicals Agency
Published: 20/03/2013

Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

Contents

1	IDENTITY OF THE SUBSTANCE.....	3
1.1	Name and other identifiers of the substance	3
2	CLASSIFICATION AND LABELLING.....	4
2.1	Harmonised Classification in Annex VI of the CLP	4
2.2	Proposal for Harmonised Classification in Annex VI of the CLP	4
2.3	Self classification	4
3	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE ...	4
3.1	Legal basis for the proposal	4
3.2	Grounds for concern	5
3.3	Information on aggregated tonnage and uses	5
3.4	Other completed/ongoing regulatory processes that may affect suitability for substance evaluation	6
3.5	Information to be requested to clarify the suspected risk	6
3.6	Potential follow-up and link to risk management	6

1 IDENTITY OF THE SUBSTANCE


1.1 Name and other identifiers of the substance

Table 1: Substance identity

Public Name:	2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
EC number:	200-076-7
EC name:	2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
CAS number (in the EC inventory):	51-03-6
CAS number:	51-03-6
CAS name:	
IUPAC name:	5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6-propyl-1,3-benzodioxole
Index number in Annex VI of the CLP Regulation	
Molecular formula:	C ₁₉ H ₃₀ O ₅
Molecular weight or molecular weight range:	338.4385
Synonyms:	PBO, 5-[2-(2-butoxyethoxymethyl)]-6-propyl-1,3-benzodioxole Common name (ISO): Piperonyl butoxide

Type of substance Mono-constituent Multi-constituent UVCB

Structural formula:



2 CLASSIFICATION AND LABELLING

2.1 Harmonised Classification in Annex VI of the CLP

No harmonised entry available.

2.2 Proposal for Harmonised Classification in Annex VI of the CLP

No proposal for harmonised classification

2.3 Self classification

In registration data self classified for: **According to CLP**

Registration 1:

Aquatic chronic 1; H410: Very toxic to aquatic life with long lasting effects.

Registration 2:

Aquatic chronic 2; H411: Toxic to aquatic life with long lasting effects.

According to DSD

1: N; R50/53: Dangerous for the environment; Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

2: N; R51/53: Dangerous for the environment; Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Additionally in the C&L data inventory database self classification is done for:

Acute Toxicity 1; H330: fatal if inhaled.

Acute Toxicity 2; H310: Fatal in contact with skin.

Acute Toxicity 3; H331: toxic if inhaled.

Aquatic Acute 1; H400: Very toxic to aquatic life.

Reproductive toxicity 2; H361: Suspected of damaging fertility or the unborn child.

3 JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE

3.1 Legal basis for the proposal

Article 44(1) (refined prioritisation criteria for substance evaluation)

Article 45(5) (Member State priority)

3.2 Grounds for concern

<input type="checkbox"/> (Suspected) CMR	<input checked="" type="checkbox"/> Wide dispersive use	<input type="checkbox"/> Cumulative exposure
<input type="checkbox"/> (Suspected) Sensitiser	<input checked="" type="checkbox"/> Consumer use	<input type="checkbox"/> High RCR
<input checked="" type="checkbox"/> (Suspected) PBT	<input type="checkbox"/> Exposure of sensitive populations	<input type="checkbox"/> Aggregated tonnage
<input checked="" type="checkbox"/> Suspected endocrine disruptor	<input type="checkbox"/> Other (provide further details below)	

Information from databases:

EC Endocrine Substances Database	Conclusion: Potential evidence of ED effects Human Health: CAT3b Wildlife CAT2
QSAR toolbox profiler ERBA	NO ER Binding Alert
Predicted ERBA TIMES	
FDA Endocrine Screening Database	

Uses indicate wide dispersive use for professional workers and consumers. Additional information from ProSP indicates uses in consumer products.

Repeated dose toxicity indicates liver and kidney as target organs. In a 2year rat carcinogenicity test amongst other effects, reduced growth and enlargement of ovaries, thyroid and small testes was noted.

The substance is concluded negative for genotoxicity.

Information in registration dossier for reproductive toxicity is not detailed in the robust study summary and the registrant conclusion for the 2 generation and developmental toxicity tests is of no concern for fertility and teratogenicity.

3.3 Information on aggregated tonnage and uses

<input type="checkbox"/> 1 - 10 tpa	<input checked="" type="checkbox"/> 10 - 100 tpa	<input type="checkbox"/> 100 - 1000 tpa
<input type="checkbox"/> 1000 - 10,000 tpa	<input type="checkbox"/> 10,000 - 100,000 tpa	
<input type="checkbox"/> 100,000 - 1000,000 tpa	<input type="checkbox"/> > 1000,000 tpa	

Confidential

Note: In addition to the above ticked tonnage there is another registration where the tonnage band is confidential.

<input checked="" type="checkbox"/> Industrial use	<input checked="" type="checkbox"/> Professional use	<input checked="" type="checkbox"/> Consumer use	<input type="checkbox"/> Closed System
--	--	--	--

3.4 Other completed/ongoing regulatory processes that may affect suitability for substance evaluation

<input type="checkbox"/> Compliance check	<input type="checkbox"/> Dangerous substances Directive 67/548/EEC
<input type="checkbox"/> Testing proposal	<input type="checkbox"/> Existing Substances Regulation 793/93/EEC
<input type="checkbox"/> Annex VI (CLP)	<input type="checkbox"/> Plant Protection Products Regulation 91/414/EEC
<input type="checkbox"/> Annex XV (SVHC)	<input checked="" type="checkbox"/> Biocidal Products Directive 98/8/EEC
<input type="checkbox"/> Annex XIV (Authorisation)	<input type="checkbox"/> Other (provide further details below)
<input type="checkbox"/> Annex XVII (Restriction)	
The substance is under Review as a Biocidal active substance, it is needed to consider if information and evaluation on ED could already take place under the BPD.	

3.5 Information to be requested to clarify the suspected risk

<input checked="" type="checkbox"/> Information on toxicological properties	<input type="checkbox"/> Information on physico-chemical properties
<input type="checkbox"/> Information on fate and behaviour	<input checked="" type="checkbox"/> Information on exposure
<input checked="" type="checkbox"/> Information on ecotoxicological properties	<input checked="" type="checkbox"/> Information on uses
<input type="checkbox"/> Other (provide further details below)	
Evaluation of the available information regarding potential for ED (EC List), together with potential PBT properties and exposure considerations.	

3.6 Potential follow-up and link to risk management

<input type="checkbox"/> Restriction	<input type="checkbox"/> Harmonised C&L	<input type="checkbox"/> Authorisation	<input type="checkbox"/> Other (provide further details)
No immediate action based on available data foreseen.			